EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtMetaanalyseOpen Access

What is the association of polypharmacy with frailty in heart failure? A systematic review and meta-analysis

Konstantinos Prokopidis, Giuseppe Dario Testa, Nicola Veronese, Yannis Dionyssiotis, Joseph McLean, Lauren E Walker, Rajiv Sankaranarayanan

Journal of Frailty, Sarcopenia and Falls · 01.03.2024 · 9 (1) · 51-65

DOI: 10.22540/jfsf-09-051 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Frailty, Sarcopenia and Falls, online erschienen am 01.03.2024. Verfasst von Konstantinos Prokopidis und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Musculoskeletal Science & Ageing, University of Liverpool, Liverpool, United Kingdom. Die Arbeit wurde bisher 10-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This systematic review and meta-analysis aimed to explore the differences in the number of prescribed medications and polypharmacy risk between patients with heart failure (HF) and frailty vs. those with HF but without frailty. Eligible studies included observational or experimental studies in patients aged ≥50 years. Thirteen studies met the criteria and were included in the final analysis. Patients with frailty and HF exhibited a higher risk of polypharmacy (OR: 1.87, 95% CI 1.72 - 2.04, I2 = 0%, P < 0.01) compared to those without frailty. Results remained significant after adjusting for comorbidity status. Additionally, patients with frailty and HF were prescribed more medications compared to those without (k = 6; MD: 1.43, 95% CI 0.31 - 2.55, I2 = 94%, P = 0.01), with a high degree of heterogeneity. However, results were non-significant after adjustment for comorbidity status. Patients with HF and frailty have a higher need of polypharmacy compared to those without frailty, which may increase the risk of potentially inappropriate medications (PIM). Investigating the real-world prevalence of PIM may support clinicians in their routine assessment as part of a comprehensive management strategy in patients with HF and frailty.

Schlagwörter

Stichwörter der Autor:innen

FrailtyHeart failureMedicationsPIMPolypharmacy

Autor:innen und Institutionen

  • Department of Musculoskeletal Science & Ageing, University of Liverpool, Liverpool, United Kingdom.
  • Department of Geriatric and Intensive Care Medicine, Careggi Hospital, University of Florence, Florence, Italy.
  • Unit of Geriatrics, Department of Internal Medicine and Geriatrics, University of Palermo, Palermo, Italy.
  • 2 Physical Medicine and Rehabilitation Department, National Rehabilitation Center EKA, Athens, Greece.
  • Androlabs, London, United Kingdom.
  • Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom.

Zitieren

APA

Prokopidis, K., Testa, G. D., Veronese, N., Dionyssiotis, Y., McLean, J., Walker, L. E., & Sankaranarayanan, R. (2024). What is the association of polypharmacy with frailty in heart failure? A systematic review and meta-analysis. Journal of Frailty, Sarcopenia and Falls, 9(1), 51-65. https://doi.org/10.22540/jfsf-09-051

Vancouver

Prokopidis K, Testa GD, Veronese N, Dionyssiotis Y, McLean J, Walker LE, et al. What is the association of polypharmacy with frailty in heart failure? A systematic review and meta-analysis. Journal of Frailty, Sarcopenia and Falls. 2024;9(1):51-65. doi:10.22540/jfsf-09-051

BibTeX
@article{Prokopidis2024,
  author = {Prokopidis, Konstantinos and Testa, Giuseppe Dario and Veronese, Nicola and Dionyssiotis, Yannis and McLean, Joseph and Walker, Lauren E and Sankaranarayanan, Rajiv},
  title = {What is the association of polypharmacy with frailty in heart failure? A systematic review and meta-analysis},
  journal = {Journal of Frailty, Sarcopenia and Falls},
  year = {2024},
  volume = {9},
  number = {1},
  pages = {51--65},
  doi = {10.22540/jfsf-09-051}
}
Kostenlos starten →